The particular interest in assessing serum TK1 activity in response to CDK4/6 inhibitors stems from the known cell cycle-inhibitory properties of these agents and their importance in the management of patients with advanced HR+ breast cancer [18, 32]. The gene discussed is CDK4; the disease is breast cancer.